GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ProPhase Labs Inc (NAS:PRPH) » Definitions » Piotroski F-Score

ProPhase Labs (ProPhase Labs) Piotroski F-Score : 1 (As of Apr. 27, 2024)


View and export this data going back to 1995. Start your Free Trial

What is ProPhase Labs Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 1 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ProPhase Labs has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for ProPhase Labs's Piotroski F-Score or its related term are showing as below:

PRPH' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 6
Current: 1

During the past 13 years, the highest Piotroski F-Score of ProPhase Labs was 6. The lowest was 1. And the median was 4.


ProPhase Labs Piotroski F-Score Historical Data

The historical data trend for ProPhase Labs's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProPhase Labs Piotroski F-Score Chart

ProPhase Labs Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 2.00 6.00 6.00 1.00

ProPhase Labs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 5.00 2.00 2.00 1.00

Competitive Comparison of ProPhase Labs's Piotroski F-Score

For the Diagnostics & Research subindustry, ProPhase Labs's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProPhase Labs's Piotroski F-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was 0.55 + -3.44 + -5.141 + -8.751 = $-16.78 Mil.
Cash Flow from Operations was 0.476 + -6.957 + -4.654 + -0.213 = $-11.35 Mil.
Revenue was 19.303 + 13.217 + 8.365 + 3.499 = $44.38 Mil.
Gross Profit was 10.52 + 6.448 + 2.327 + -3.056 = $16.24 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(87.648 + 95.374 + 91.058 + 91.71 + 91.927) / 5 = $91.5434 Mil.
Total Assets at the begining of this year (Dec22) was $87.65 Mil.
Long-Term Debt & Capital Lease Obligation was $18.59 Mil.
Total Current Assets was $47.59 Mil.
Total Current Liabilities was $20.86 Mil.
Net Income was 12.494 + 7.446 + 0.968 + -2.444 = $18.46 Mil.

Revenue was 47.531 + 29.092 + 24.2 + 21.823 = $122.65 Mil.
Gross Profit was 28.677 + 18.72 + 11.973 + 11.283 = $70.65 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(89.295 + 99.665 + 97.947 + 97.877 + 87.648) / 5 = $94.4864 Mil.
Total Assets at the begining of last year (Dec21) was $89.30 Mil.
Long-Term Debt & Capital Lease Obligation was $6.66 Mil.
Total Current Assets was $60.83 Mil.
Total Current Liabilities was $16.08 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ProPhase Labs's current Net Income (TTM) was -16.78. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ProPhase Labs's current Cash Flow from Operations (TTM) was -11.35. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-16.782/87.648
=-0.19147043

ROA (Last Year)=Net Income/Total Assets (Dec21)
=18.464/89.295
=0.2067753

ProPhase Labs's return on assets of this year was -0.19147043. ProPhase Labs's return on assets of last year was 0.2067753. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

ProPhase Labs's current Net Income (TTM) was -16.78. ProPhase Labs's current Cash Flow from Operations (TTM) was -11.35. ==> -11.35 > -16.78 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=18.587/91.5434
=0.20304031

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=6.659/94.4864
=0.07047575

ProPhase Labs's gearing of this year was 0.20304031. ProPhase Labs's gearing of last year was 0.07047575. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=47.585/20.857
=2.28148823

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=60.833/16.075
=3.78432348

ProPhase Labs's current ratio of this year was 2.28148823. ProPhase Labs's current ratio of last year was 3.78432348. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

ProPhase Labs's number of shares in issue this year was 18.056. ProPhase Labs's number of shares in issue last year was 16.244. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=16.239/44.384
=0.36587509

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=70.653/122.646
=0.5760726

ProPhase Labs's gross margin of this year was 0.36587509. ProPhase Labs's gross margin of last year was 0.5760726. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=44.384/87.648
=0.50638919

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=122.646/89.295
=1.37349236

ProPhase Labs's asset turnover of this year was 0.50638919. ProPhase Labs's asset turnover of last year was 1.37349236. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+0+0
=1

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ProPhase Labs has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

ProPhase Labs  (NAS:PRPH) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


ProPhase Labs Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of ProPhase Labs's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ProPhase Labs (ProPhase Labs) Business Description

Traded in Other Exchanges
N/A
Address
711 Stewart Avenue, Suite 200, Garden City, NY, USA, 11530
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
Executives
Morse Robert A. Jr. officer: Controller 711 STEWART AVENUE, SUITE 200, GARDEN CITY NY 11530
Billy Joe White officer: Chief Financial Officer 191 OTTO ST., PORT TOWNSEND WA 98368
Jason Michael Barr director 902 BROADWAY, 15TH FLOOR, NEW YORK NY 10010
Louis Md Gleckel 10 percent owner C/O PROHEALTH CARE ASSOCIATES LLP, 2800 METRUS AVE, LAKE SUCCESS NY 11042
Ted William Karkus 10 percent owner 188 HEWLETT NECK ROAD, WOODMERE NY 11598
Warren Hirsch director 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Monica L. Brady officer: Chief Accounting Officer 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Cuddihy Robert V Jr officer: Chief Operating Officer PARKER DURYEE ET AL, 529 FIFTH AVE 8TH FL, NEW YORK NY 10017
Braden Michael Leonard 10 percent owner 156 S. FIRST STREET, ZIONSVILLE IN 46077
Mark S Leventhal 10 percent owner THE BEACON COMPANIES, 50 FEDERAL STREET, BOSTON MA 02468
Mark Shawn Frank director 104 WHISPER WOOD COURT, WRIGHTSTOWN PA 18940
James T Mccubbin director
Mark A. Burnett 10 percent owner 40 HEMLOCK DRIVE, ROSLYN NY 11576
Guy J Quigley director, 10 percent owner, officer: Chairman, President, CEO C/O THE QUIGLEY CORP KELLS BUILDINGS, 621 SHADY RETREAT RD P O BOX 1349, DOYLESTOWN PA 18901
John Deshazo 10 percent owner 17 WOLCOTT COURT, BOSTON MA 02136

ProPhase Labs (ProPhase Labs) Headlines

From GuruFocus